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Objectives: Nitric oxide (NO), produced by normal vascular endothelial cells, reduces platelet aggregation and thrombus
formation. NO-releasing biopolymers have the potential to prolong vascular graft and stent patency without adverse
systemic vasodilation.
Methods: 5-mm polyurethane vascular grafts coated with a polymer containing the NO-donor dialkylhexanediamine
diazeniumdiolate were implanted for 21 days in a sheep arteriovenous bridge-graft model.
Results: Eighty percent (4/5) of grafts coated with the NO-releasing polymer remained patent through the 21 day
implantation period, compared to fifty percent (2/4) of sham-coated grafts and no (0/3) uncoated grafts. Thrombus-free
surface area (SEM) of explanted grafts was significantly increased in NO-donor coated grafts (98.2% 0.9%) compared
with sham-coated (79.2%  8.6%) and uncoated (47.2%  5.4%) grafts (P  .00046). Examination of the graft surface
showed no adherent thrombus or platelets and no inflammatory cell infiltration in NO-donor coated grafts, while control
grafts showed adherent complex surface thrombus consisting of red blood cells in an amorphous fibrin matrix, as well as
significant red blood cell and inflammatory cell infiltration into the graft wall.
Conclusion: In this study we determined that local NO release from the luminal surface of prosthetic vascular grafts can
reduce thrombus formation and prolong patency in a model of prosthetic arteriovenous bridge grafts in adult sheep.
These findings may translate into improved function and improved primary patency rates in small-diameter prosthetic
vascular grafts. ( J Vasc Surg 2004;40:803-11.)
Clinical Relevance: Early (within 30 days) small-diameter prosthetic graft occlusion is common; low conduit flow volume
and inherent thrombogenicity are believed to be the major factors in the cause of occlusion. In this study small-diameter
arteriovenous bridge grafts were coated with a new nitric oxide–releasing biopolymer, resulting in an increased
thrombus-free graft surface area. With the results of this study it is reasonable to hypothesize that prevention of early
thrombus formation may translate into improved primary patency rates in small-diameter prosthetic vascular grafts.Over the last decade the numbers of surgical revascu-
larization procedures, including coronary and lower ex-
tremity bypass, have increased dramatically, owing in part
to the aging population.1 Furthermore, the number of
secondary vascular procedures is estimated at 15% after
initial coronary revascularization and approximately 50%
after lower extremity bypass.2,3 Similarly, the number of
patients requiring vascular access for hemodialysis has in-
creased significantly, and is currently estimated at 250,000
persons in the United States, of whom 70% receive pros-
thetic vascular grafts as the primary vascular access.4 To-
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doi:10.1016/j.jvs.2004.07.007gether, these data suggest an increasing clinical need for
small-diameter prosthetic vascular grafts in the future.
Because of superior patency, autogenous bypass con-
duits are preferred for primary revascularization proce-
dures. The increasing incidence of secondary procedures in
the aging patient population suggests a growing need for
alternatives when autogenous conduits are unavailable or
are inadequate.5 Despite this accelerating need for vascular
conduits in small-diameter bypass and hemodialysis grafts,
early thrombosis (30 days) remains a formidable obstacle
to their widespread applicability. Early thrombosis is esti-
mated to occur in as many as 25% of prosthetic infrapopli-
teal bypass grafts and 18% of prosthetic hemodialysis access
grafts.3,6-8 Early thrombosis in small-diameter (6 mm)
conduits is primarily a result of graft thrombogenicity and
reduced flow volume.3,7,9 Recent research to prolong pa-
tency of small-diameter prosthetic grafts has focused pri-
marily on the activity of platelets and the nature of the graft
material to prevent thrombus formation.10-14 On the other
hand, subacute thrombosis (1-18 months) is thought to
result from altered flow dynamics produced by develop-
ment of intimal hyperplasia, primarily at the distal anasto-
mosis.6803
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thelial cells, limits platelet activation, adhesion, and aggre-
gation by activating guanylyl cyclase, inhibiting phospho-
inositide 3-kinase, impairing capacitative calcium influx,
and inhibiting cyclooxygenase-1,15,16 preventing the adhe-
sive receptor-ligand interactions that promote thrombus
formation and growth.17 However, profound vasodilatory
effects limit the use of NO in pharmacologic doses in
vivo.18 Nevertheless, because NO is rapidly scavenged by
oxygen and hemoglobin in plasma, local release of NO by
NO-releasing biopolymers has the potential to prolong
vascular graft and stent patency without adverse systemic
vasodilation.13 For example, in a previous study in ba-
boons, NO-releasing arteriovenous grafts reduced indium
111–labeled platelet aggregation, compared with control
grafts.16 In a similar study that used extracorporeal circula-
tion circuits, NO-releasing polymer significantly reduced
platelet adhesion without adverse physiologic effects in a
rabbit model.10
In the present study we explored the hypothesis that
local NO release from the luminal surface of prosthetic
vascular grafts reduces thrombus formation and prolongs
graft patency in vivo. Small-diameter vascular grafts were
coated with a new NO-releasing biopolymer. When ex-
posed to physiologic conditions the polymer releases
NO gas without releasing appreciable amounts of the
dialkyldiamine-based diazeniumdiolate NO donor com-
pound or other by-products of the NO release reaction.
The grafts were placed as arteriovenous bridge grafts in
adult sheep, and were explanted at 21 days for evaluation.
Patency was determined at clinical and ultrasound exami-
nations, and thrombus formation was measured as gross
thrombus-free surface area (TFSA) and graft histologic
findings. NO-releasing biopolymers significantly reduced
thrombus formation and increased overall patency in these
grafts. These results suggest that NO-releasing biopoly-
mers may improve patency of small-diameter prosthetic
vascular grafts.
MATERIAL AND METHODS
Graft preparation. Small-diameter polyurethane vas-
cular grafts (5-mm internal diameter, 25 cm long; Vectra
vascular access graft, Bard-Impra) were coated with a pre-
viously characterized NO-releasing biopolymer (MC3
Corp).14 Vascular grafts were dip-coated with multiple
layers of plasticized polyvinyl chloride containing the NO
donor dialkylhexanediamine diazeniumdiolate. Control
grafts were either uncoated or sham-coated polyurethane
grafts of equivalent diameter and length. Sham-coated
control grafts were prepared with the same polymer layer
used in the NO-releasing grafts; however, the NO-releas-
ing compound present within the polymer was absent. The
NO-releasing compound, or NO donor, is a previously
described and well-characterized dialkylhexanediamine
diazeniumdiolate compound.13 The principles of the activ-
ity of this new NO-releasing biopolymer are outlined in Fig
1. After sterilization, a 1-cm piece of coated graft material
was removed and retained for in vitro assay of NO release byon-line chemiluminescence. The 1-cm long sections of the
vascular graft were soaked in phosphate-buffered saline
solution (PBS; pH 7.4, 37°C) for selected time intervals.
NO surface flux was calculated on the basis of surface area
of the graft and the NO release profile.13 The grafts were
blinded after coating, and were implanted, harvested, and
processed in blinded fashion. The grafts were not un-
blinded until data collection was complete.
Animal model. All animal experiments were approved
by the William Beaumont Hospital Animal Care Commit-
tee and complied with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.19
Six adult male sheep (35-45 kg) underwent an initial
procedure for blinded placement of bilateral arteriovenous
bridge grafts from the distal common carotid arteries to the
ipsilateral external jugular veins. Aspirin (325 mg) per
rectum was given daily to each animal, starting on the day
of the operation. All sheep were anesthetized with intrave-
nously administered ketamine hydrochloride (22 mg/kg),
and all received orotracheal tubes. Mechanical ventilation
with inhaled isoflurane was used for maintenance anesthe-
sia. An intravenous infusion was maintained via a forefoot
vein throughout the procedure.
Sheep were initially positioned in the right lateral de-
cubitus position, to expose the left side of the neck, with the
neck slightly extended. The proximal left external jugular
vein and distal left common carotid artery were exposed
through individual incisions, and were connected with a
subcutaneous tunnel for the graft. Once the vessels were
exposed and the tunnel created, intravenous heparin so-
dium at 200 U/kg was given, and supplemented every 90
minutes with an additional 100 U/kg. Standard end-to-
side vascular anastomoses were created with continuous
6-0 polypropylene suture. After completion of the anasto-
mosis flow was restored, and a palpable thrill was appreci-
ated within the graft. Local hemostasis was obtained, and
the left-side incision was closed in layers. The sheep were
then turned to the left lateral decubitus position for expo-
sure of the right side of the neck. The graft on the right side
was placed in an identical manner. Feeding was reinstituted
on the first postoperative day. With the same anesthesia and
positioning as described for the initial procedure, all grafts
were explanted at 21 days. Complete in situ exposure of
each side enabled visualization to assess for any mechanical
problems.
Patency. Palpation and auscultation were performed
daily to assess for graft patency. Patency was defined as the
presence of a palpable thrill, audible bruit, or both. In any
sheep for which examination findings were equivocal, du-
plex ultrasound scanning was performed with the animal
under ketamine sedation, to further assess graft status.
Pre-arterial and post-arterial anastomotic flow velocity and
venous outflow velocity were measured. Because these
polyurethane grafts are highly echogenic, direct ultrasound
measurements cannot be made of flow velocity within the
graft. Failure to demonstrate a decrease in flow velocity
across the arterial anastomosis or lack of arterial flow veloc-
ity at the venous anastomosis was considered consistent
red b
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explantation by the presence of an intraoperative palpable
thrill, in addition to aspiration of arterial blood at mid-graft
before ligation. Coagulation status was not monitored dur-
ing the period of implantation.
TFSA. At explantation all grafts were immediately
flushed with 10 mL of normal saline solution to remove
fresh thrombus and blood. To preserve the grafts for gross
and histologic sectioning, perfusion fixation with 2.5%
glutaraldehyde solution was performed at physiologic pres-
sure for 5 minutes. To determine the effect of NO-releasing
biopolymer on surface thrombus formation, percent TFSA
for each graft was measured with Optimas image processing
software (Media Cybernetics). Grafts were opened longitu-
dinally, and a high-resolution digital image was captured.
Image characteristics identified as indicative of surface
thrombus were assigned color levels in the programming,
and percent of graft surface area corresponding to TFSA
was computed. On average 5 repeat, nonsequential analyses
of each graft segment were performed. Validation studies of
this technique have shown that repeat measures performed
in blinded fashion on the same sample typically show a
variance of less than 5%.20
Histologic analysis. Graft specimens were taken for
histologic analysis through the graft at the venous anasto-
mosis. This is a common site of flow disturbances, and is
thought to represent an area of increased thrombogenic
potential. Specimens were fixed in 10% neutral buffered
Fig 1. Schematic representation of nitric oxide (NO
NO-releasing graft is a thin layer of pure polymer outer co
Beneath the outer coating is a PVC polymer suspension
diffuses from the blood, it contacts the NO-releasing com
into the lumen of the vessel, where local activity on platele
is quickly scavenged by oxygen and hemoglobin of localformalin and embedded in paraffin. Five-micrometer sec-
tions were cut perpendicular to the axis of the vessel
through the spatulated toe of the graft. Sections were
stained with hematoxylin-eosin and examined for location,
thickness, and structure of any thrombus. Cellular organi-
zation and matrix formation were examined by staining
with Movat pentachrome stain, which differentiates colla-
gen, elastin, mucin, and ground substance, fibrin, muscle,
and cell nuclei.
Scanning electron microscopy. Surface characteris-
tics such as fibrin layering and platelet adherence were
evaluated with scanning electron microscopy. After gross
photography, scanning electron microscopy specimens (8
mm  6 mm) were taken from the arterial and venous
anastomoses and from the central graft area. Specimens
were processed with standard methods of osmium tetrox-
ide after fixation, dehydration, and critical point drying.
Dried specimens were affixed to specimen mounts with
double-sided tape. Specimens were coated with 15 nm of
gold-palladium, and were examined with a JEOL 6400
scanning electron microscope at 8 kV. Images were re-
corded on Polaroid P/N 55 film.
Statistical analysis. Differences in percentage of
TFSA between NO-releasing grafts and control grafts were
analyzed with analysis of variance followed with the Stu-
dent unpaired t test (two-tailed), and the Fisher exact test
was used to determine the significance of patency differ-
ase from polymer coating. At luminal surface of the
consisting entirely of polyvinyl chloride (PVC) polymer.
ining the NO-releasing compound (NO-RC). As water
d within the suspension. This enables release of free NO
stablished. Systemic NO effects are averted, because NO
lood cells.) rele
ating
conta
poun
ts is e
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P  .05.
RESULTS
Twelve grafts (5 NO-releasing grafts, 4 sham-coated
control grafts, 3 uncoated control grafts) were placed in 6
sheep in a blinded, randomized fashion. In 4 animals both
grafts were implanted simultaneously, and in 2 sheep the
grafts were implanted sequentially (Table I). Because the
graft distribution was blinded, randomization of the grafts
resulted in some sheep receiving 2 identical grafts and other
sheep receiving different grafts.
There were no obvious mechanical problems (eg, twist-
ing, kinking) in any graft at removal. Patency was con-
firmed by the presence of audible bruit, palpable thrill, and
needle aspiration of arterial blood at explantation. All grafts
determined to be thrombosed before 21 days were con-
firmed as occluded at explantation by lack of audible bruit
and palpable thrill, and failure to produce arterial blood at
needle aspiration. Duplex ultrasound scanning was used on
4 separate occasions to confirm graft status. On all 4
occasions, lack of arterial flow velocity change across the
arterial anastomosis and failure to demonstrate arterial flow
velocity at the venous anastomosis confirmed the clinical
suspicion of thrombosis of the graft.
Patency. Patency of each graft was determined at clin-
ical and ultrasound examination, and confirmed intraoper-
atively at explantation. At explantation, both grafts were
occluded in 2 sheep, both grafts were patent in 2 sheep, and
1 graft was occluded and 1 graft was patent in 2 sheep. All
Table II. Mean percent thrombus-free surface area for
all grafts with statistical comparison between groups
Graft type % TFSA  SEM
NO-releasing graft 98.2  0.9
Sham-coated control graft 79.2 8.6
Uncoated graft 47.2  5.4
TFSA, Thrombus-free surface area; NO, nitric oxide.
P  .000446 at 1-way variable analysis of variance.
Table I. Distribution of grafts in experimental animals
Identifier Graft type
Animal 1 Uncoated control graft
Uncoated control graft
Animal 2 Uncoated control graft
Sham-coated graft
Animal 3 NO-releasing graft
NO-releasing graft
Animal 4 Sham-coated graft
NO-releasing graft
Animal 5 Sham-coated graft
NO-releasing graft
Animal 6 Sham-coated graft
NO-releasing graft
NO, Nitric oxide.3 uncoated control grafts were determined to be throm-
bosed at clinical and duplex ultrasound scanning before 21
days (3, 7, and 12 days; mean, 7 days). Of the 4 sham-
coated control grafts, 2 were thrombosed, both at 12 days,
and 2 remained patent at 21 days. Of the 5 NO-releasing
grafts, 1 was thrombosed at 18 days and 4 remained patent
at 21 days. Overall, improved patency between NO-releas-
ing grafts and control grafts did not reach statistical signif-
icance (Table II).
TFSA. With the Optimas system TFSA was deter-
mined for the entire luminal surface of each graft. A statis-
tically significant increase in TFSA was seen with the
NO-releasing grafts compared with both uncoated and
sham-coated control grafts. In 5 NO-releasing grafts, TFSA
averaged 98.2% (range, 95.1%-99.6%). In 4 sham-coated
control grafts TFSA averaged 79.2% (range, 56.6%-97.9%).
In 3 uncoated control grafts TFSA averaged 47.2% (range,
37.6%-56.3%; (Fig 2). Statistical comparison of mean per-
cent TFSA is shown in Table III.
Histologic analysis. Examination of hematoxylin-
eosin–stained light microscopy sections at 40 magnifica-
tion showed significant thrombus adherent to the luminal
surface of the uncoated control graft. The complex throm-
bus had a maximum thickness of 200 m, and consisted of
red blood cells in a heavy fibrin matrix, with a few inflam-
matory cells. Within the graft wall a significant increase was
noted in the number of inflammatory cells and red blood
cell infiltration. Similar histologic sections of the NO-
releasing graft showed the luminal surface to be free of
thrombus, with occasional minor deposits of thin matrix
Table III. Graft patency at 21 days with statistical
comparison between groups
Graft type Patency (21 days)
NO-releasing graft 4 of 5
Sham-coated control graft 2 of 4
Uncoated graft 0 of 3
P  .071 (NO-releasing graft vs uncoated graft; Fisher exact test).
P  .405 (NO-releasing graft vs sham-coated graft; Fisher exact test).
Implantation
order Patency status
Simultaneous Occluded day 3
Occluded day 12
Sequential Occluded day 9
Occluded day 12
Sequential Occluded day 18
Open at explantation
Simultaneous Open at explantation
Open at explantation
Simultaneous Open at explantation
Open at explantation
Simultaneous Occluded day 12
Open at explantation
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 4 Fleser et al 807fragments and the graft containing only a few scattered red
blood cells and inflammatory cells (Fig 3). Specimens from
sham-coated grafts showed variable amounts of thrombus,
which did not appear to be strongly adherent to the graft
surface at the venous anastomosis. Staining of NO-releas-
ing grafts with Movat pentachrome showed occasional
areas of the polymer coating covered with a noncontinu-
ous, approximately 2-m layer of fibrin matrix.
Scanning electron microscopy. Surface characteris-
tics such as fibrin layering and platelet adherence were
evaluated with scanning electron microscopy; Fig 4 shows
representative images. Although there was variability be-
tween specimens, the arterial anastomosis of sham-coated
grafts generally showed a fibrin coating and dense scatter-
ing or clusters of activated platelets, and 20% to 50%
coverage with red blood cells, and some specimens showed
complete coverage with complex thrombus consisting of
red blood cells and occasional inflammatory cells in a heavy
fibrin matrix. The arterial anastomosis of NO-releasing
grafts also showed some variability, but had less than 30%
coverage with red blood cells, and scattered or few small
clusters of mostly inactivated platelets, with small thrombi
around the sutures. Venous anastomoses of sham-coated
grafts also showed a fibrin coating and 20% to 30% coverage
with red blood cells or thrombus; platelets were generally
scattered. Venous anastomoses of NO-releasing grafts were
similar. Specimens from the central position of sham-
coated grafts showed 10% to 50% red blood cell coverage,
with generally scattered, inactivated platelets and some
platelet clusters in occasional specimens. Specimens from
the central portion of NO-releasing grafts were highly
variable, and ranged from mostly clear with a few scattered
platelets to 1 specimen with 85% to 90% coverage with red
blood cells and platelet clusters.
Fig 2. Representative gross photographs of explanted p
to display luminal thrombus. A, Uncoated control g
biopolymer. C, Graft incorporating nitric oxide–releasinNO release. NO release rates measured in vitro from
samples of grafts reserved at implantation demonstrated
persistent NO production after the first week at 29.2 
1012 mol cm2 sec1, and this decreased slightly to 5.5
 1012 mol cm2 sec1 by 3 weeks. Kinetics of release
was linear for approximately the first week (Fig 5).
DISCUSSION
Autogenous conduits are the ideal replacements for
diseased small-diameter arteries, because of the relatively
low inherent thrombogenicity of native endothelium.5
However, when previous procedures or underlying condi-
tions have depleted autogenous options, there is need for
alternative conduits. Prosthetic grafts are routinely used for
replacement and bypass of large-diameter arteries, with a
fairly limited incidence of early thrombosis.21 In contrast,
as graft diameter decreases thrombosis is more common,
because shear stress increases under higher flow velocity
and lower flow volume.9 Moreover, the addition of a
relatively thrombogenic synthetic luminal surface makes
prosthetic conduits even less desirable for bypass of small-
diameter arteries.
Early (within 30 days) prosthetic graft occlusion is not
uncommon. As many as 18% of synthetic vascular access
conduits for dialysis become thrombosed within the first 3
weeks and can never be used.7 Moreover, as many as 25% of
infrapopliteal synthetic grafts become thrombosed within
the first month.3,6,8 Once believed to be due entirely to
technical errors, only 20% of early graft thromboses are now
thought to be the direct result of poor technique. Conduit
flow volume and inherent thrombogenicity are believed to
be the major factors, especially since smaller conduits are
being used to bypass smaller vessels.6
ethane vascular grafts. Grafts were opened longitudinally
B, Sham-coated graft without nitric oxide–releasing
ymer coating on luminal surface.olyur
raft.
g pol
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grafts were coated with a new NO-releasing biopolymer in
an effort to reduce thrombus formation and improve over-
all patency. Inasmuch as platelets are an important contrib-
utor to early thrombus formation, we introduced a
dialkylhexanediamine diazeniumdiolate NO-releasing
biopolymer that reduces platelet adhesion.13,22 Previous
studies have demonstrated that the kinetics of NO release
are linear for approximately the first week; however, the
levels of NO generated after 25 days are still greater than
the estimated rate of NO production for endothelial cells in
vivo of 5.3 to 6.8  1012 mol cm2 sec1.23,24 In the
present study, surface thrombus accumulation was signifi-
cantly less in the NO-releasing grafts compared with both
uncoated and sham-coated control grafts over a 3-week
follow-up. This interval was chosen because it represents
not only the period of maximal platelet adhesion and early
thrombus formation but also the period of maximal NO-
releasing activity from the biopolymer (Fig 5). Increased
TFSA in the early postoperative period may lead to im-
proved primary patency rates in these grafts. Moreover,
reduction in thrombus formation and early platelet adhe-
sion may improve flow volume during the period of maxi-
mal intimal hyperplastic response that follows. Although
Fig 3. A, Schematic diagram demonstrating site of his
toxylin-eosin–stained histologic sections from uncoated
uncoated graft; arrowheads, red blood cell infiltration. M
sections from nitric oxide–releasing graft. Luminal surf
attached thrombus. Cellular infiltration is not seen withi
top of photograph.we did not observe a statistically significant improvement in
patency in this study, the results for TFSA certainly suggest
a beneficial effect of local NO release on thrombus accu-
mulation on the surface of these grafts. Thus we believe that
this preliminary study in a limited cohort of animals pro-
vides compelling evidence to suggest the merit of addi-
tional investigation into the effects of NO-releasing grafts
on long-term patency.
A hypercoagulable state can be induced in sheep exper-
imentally with infusion of endotoxin25 after severe trau-
ma,26 in fetal lambs with infusion of insulin,27 and naturally
after viral infection.28-30 Thus a potential weakness of this
study is that an unrecognized hypercoagulable state, if
present in some of the animals, could markedly bias the
TFSA results, depending on the randomization schedule.
However, the pattern of graft occlusion observed in this
study suggests that a hypercoagulable state did not exist in
these animals. In 4 of the animals 2 grafts were implanted
simultaneously, and in the remaining 2 animals grafts were
implanted sequentially. In 1 of the animals with sequen-
tially implanted grafts (Table I, Animal 3), the NO-releas-
ing graft became occluded on day 18 post-implantation,
whereas the subsequently implanted NO-releasing graft
remained open until explantation, with TFSA of 97.4%.
ic sections of arteriovenous graft specimens. B, Hema-
t. Note abundance of thrombus at luminal surface of
ification 40. C, Hematoxylin-eosin–stained histologic
as thin fibrin coating in some specimens, but is free of
graft wall. Magnification 40. Luminal surface towardtolog
graf
agn
ace h
n the
x.
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only the sham-coated graft occluded at day 12, had a
second, NO-releasing graft, which remained patent
throughout the study, with TFSA of 99.3%. It is reasonable
to assume that any significant hypercoagulable state should
affect both grafts. Thus, although we did not specifically
test for the presence of a hypercoagulable state, we believe
that the randomization patterns and patency results argue
against the presence of a significant hypercoagulable state
in these animals.
The present study has a number of methodologic lim-
itations. First, the sheep model may not be representative of
the human condition. Sheep were ultimately chosen be-
cause of their uniformity, suitable vessel sizes, similarity of
coagulation system to that in human beings, ease of neck
Fig 4. Explanted grafts were examined with scanning e
accumulation on graft surfaces. A-D, Magnification
anastomoses of 2 different nitric oxide–releasing grafts.
background of thin fibrils. Isolated platelets and 5% to 2
specimens. Most platelets appear inactivated when viewe
tative specimens from arterial anastomoses of 2 sham-coa
red and white blood cells, isolated platelets, and platelet c
magnification (not shown). Specimen D shows complete
and occasional inflammatory cells in a heavy fibrin matridissection, and the possibility of producing chronic renal
failure to study the effects of uremia on graft function in the
future. Second, the arteriovenous bridge graft model, while
relevant to the flow hemodynamics of hemodialysis access
grafts, may not be representative of the hemodynamic
conditions in small-diameter prosthetic vascular grafts used
to bypass coronary arteries or tibial arteries in the lower
extremity. Moreover, there is now increasing evidence that
factors that influence graft patency may be specific to the
site and the vascular bed.31-34 While the present model has
the obvious advantage of being analogous to the standard
arteriovenous loop grafts used for vascular access for hemo-
dialysis in human beings, these observations may not be
generalizable to prosthetic arterio-arterial bypass grafts
used in conventional coronary or peripheral revasculariza-
n microscopy to show platelet adhesion and thrombus
0. A and B, Representative specimens from arterial
coating of fibrin is visible in specimen A as a mottled
overage of red and white blood cells are noted in both
higher magnification (not shown). C and D, Represen-
rafts. Specimen C shows approximately 50% coverage of
s. Some platelets appear activated when viewed at higher
age with complex thrombus consisting of red blood cellslectro
100
Thin
0% c
d at
ted g
lump
cover
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thrombus accumulation is a necessary precursor to com-
plete graft thrombosis. Thus we believe the results of the
present study provide supportive preliminary data for future
studies in an arterio-arterial bypass model.
Finally, NO also reduces smooth muscle cell prolifera-
tion and migration, which are important factors in the
intimal hyperplastic response.18 NO also inhibits leukocyte
adhesion, which has a major role in the intimal hyperplastic
response.18 Of interest, no study to date has shown a
significant reduction in intimal hyperplasia from NO-re-
leasing surfaces.11,18 An important question as to whether
NO-releasing biopolymers can reduce intimal hyperplasia
in the subacute period was not addressed in this study, but
is currently being evaluated in additional experiments. In
studies by Cruz et al,35 inhibiting platelet adhesion with
Saratin reduced intimal hyperplasia in a rat carotid endar-
terectomy model. With the results of the present study, it is
reasonable to hypothesize that prevention of early throm-
bus formation may have a role in abrogating the intimal
hyperplastic response. Together, the results of these studies
suggest that the effects of NO-releasing biopolymers on
intimal hyperplasia in this model may provide a fruitful area
for future investigation.
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